These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 36463696)

  • 41. Adoptive cellular immunotherapy for the treatment of patients with breast cancer: a meta-analysis.
    Wang ZX; Cao JX; Wang M; Li D; Cui YX; Zhang XY; Liu JL; Li JL
    Cytotherapy; 2014 Jul; 16(7):934-45. PubMed ID: 24794183
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bone marrow mesenchymal stem cells reduce the antitumor activity of cytokine-induced killer/natural killer cells in K562 NOD/SCID mice.
    Li Y; Qu YH; Wu YF; Wang XP; Wei J; Huang WG; Zhou DH; Fang J; Huang K; Huang SL
    Ann Hematol; 2011 Aug; 90(8):873-85. PubMed ID: 21234566
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Serum alpha-fetoprotein measurement in predicting clinical outcome related to autologous cytokine-induced killer cells in patients with hepatocellular carcinoma undergone minimally invasive therapy.
    Pan CC; Huang ZL; Li W; Zhao M; Zhou QM; Xia JC; Wu PH
    Chin J Cancer; 2010 Jun; 29(6):596-602. PubMed ID: 20507732
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Improved activation toward primary colorectal cancer cells by antigen-specific targeting autologous cytokine-induced killer cells.
    Schlimper C; Hombach AA; Abken H; Schmidt-Wolf IG
    Clin Dev Immunol; 2012; 2012():238924. PubMed ID: 22481963
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Influence of the number and interval of treatment cycles on cytokine-induced killer cells and their adjuvant therapeutic effects in advanced non-small-cell lung cancer (NSCLC).
    Gu Y; Lv H; Zhao J; Li Q; Mu G; Li J; Wuyang J; Lou G; Wang R; Zhang Y; Huang X
    Int Immunopharmacol; 2017 Sep; 50():263-269. PubMed ID: 28711032
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients.
    Jiang JT; Shen YP; Wu CP; Zhu YB; Wei WX; Chen LJ; Zheng X; Sun J; Lu BF; Zhang XG
    World J Gastroenterol; 2010 Dec; 16(48):6155-62. PubMed ID: 21182234
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cytomegalovirus-specific cytokine-induced killer cells: concurrent targeting of leukemia and cytomegalovirus.
    Pfirrmann V; Oelsner S; Rettinger E; Huenecke S; Bonig H; Merker M; Wels WS; Cinatl J; Schubert R; Klingebiel T; Bader P
    Cytotherapy; 2015 Aug; 17(8):1139-51. PubMed ID: 26072027
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antitumor activity of cytokine-induced killer cells in nude mouse xenograft model.
    Kim HM; Kang JS; Lim J; Kim JY; Kim YJ; Lee SJ; Song S; Hong JT; Kim Y; Han SB
    Arch Pharm Res; 2009 May; 32(5):781-7. PubMed ID: 19471894
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vivo distribution and antitumor effect of infused immune cells in a gastric cancer model.
    Du X; Jin R; Ning N; Li L; Wang Q; Liang W; Liu J; Xu Y
    Oncol Rep; 2012 Nov; 28(5):1743-9. PubMed ID: 22948809
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
    Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
    Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cytokine-Induced Killer Cells Kill Chemo-surviving Melanoma Cancer Stem Cells.
    Gammaitoni L; Giraudo L; Macagno M; Leuci V; Mesiano G; Rotolo R; Sassi F; Sanlorenzo M; Zaccagna A; Pisacane A; Senetta R; Cangemi M; Cattaneo G; Martin V; Coha V; Gallo S; Pignochino Y; Sapino A; Grignani G; Carnevale-Schianca F; Aglietta M; Sangiolo D
    Clin Cancer Res; 2017 May; 23(9):2277-2288. PubMed ID: 27815354
    [No Abstract]   [Full Text] [Related]  

  • 52. The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies.
    Linn YC; Niam M; Chu S; Choong A; Yong HX; Heng KK; Hwang W; Loh Y; Goh YT; Suck G; Chan M; Koh M
    Bone Marrow Transplant; 2012 Jul; 47(7):957-66. PubMed ID: 21986635
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combined therapy with cytokine-induced killer cells and oncolytic adenovirus expressing IL-12 induce enhanced antitumor activity in liver tumor model.
    Yang Z; Zhang Q; Xu K; Shan J; Shen J; Liu L; Xu Y; Xia F; Bie P; Zhang X; Cui Y; Bian XW; Qian C
    PLoS One; 2012; 7(9):e44802. PubMed ID: 23028626
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients' preference-based study (PPPS).
    Zhao Y; Qiao G; Wang X; Song Y; Zhou X; Jiang N; Zhou L; Huang H; Zhao J; Morse MA; Hobeika A; Ren J; Lyerly HK
    Clin Transl Oncol; 2019 Jun; 21(6):721-728. PubMed ID: 30374838
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In-vitro influence of mycophenolate mofetil (MMF) and Ciclosporin A (CsA) on cytokine induced killer (CIK) cell immunotherapy.
    Bremm M; Huenecke S; Zimmermann O; Pfirrmann V; Quaiser A; Bonig H; Soerensen J; Klingebiel T; Rettinger E; Bader P; Cappel C
    J Transl Med; 2016 Sep; 14(1):264. PubMed ID: 27620209
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers.
    Sangiolo D; Martinuzzi E; Todorovic M; Vitaggio K; Vallario A; Jordaney N; Carnevale-Schianca F; Capaldi A; Geuna M; Casorzo L; Nash RA; Aglietta M; Cignetti A
    Int Immunol; 2008 Jul; 20(7):841-8. PubMed ID: 18469328
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
    Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of adjuvant cytokine-induced killer cell immunotherapy in patients with colorectal cancer after radical resection.
    Pan QZ; Zhao JJ; Yang CP; Zhou YQ; Lin JZ; Tang Y; Gu JM; Wang QJ; Li YQ; He J; Chen SP; Song MJ; Huang Y; Yang JY; Weng DS; Xia JC
    Oncoimmunology; 2020; 9(1):1752563. PubMed ID: 32363125
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clearance of Hematologic Malignancies by Allogeneic Cytokine-Induced Killer Cell or Donor Lymphocyte Infusions.
    Merker M; Salzmann-Manrique E; Katzki V; Huenecke S; Bremm M; Bakhtiar S; Willasch A; Jarisch A; Soerensen J; Schulz A; Meisel R; Bug G; Bonig H; Klingebiel T; Bader P; Rettinger E
    Biol Blood Marrow Transplant; 2019 Jul; 25(7):1281-1292. PubMed ID: 30878607
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative study on anti-tumor immune response of autologous cytokine-induced killer (CIK) cells, dendritic cells-CIK (DC-CIK), and semi-allogeneic DC-CIK.
    Wang QJ; Wang H; Pan K; Li YQ; Huang LX; Chen SP; He J; Ke ML; Zhao JJ; Li JJ; Sun JC; Liang XT; Ma HQ; Chen YB; Xia JC
    Chin J Cancer; 2010 Jul; 29(7):641-8. PubMed ID: 20591215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.